Retrieve available abstracts of 16 articles: HTML format
Single Articles
July 2025
HE D, Zhang L, Yu L, Zhang Y, et al Fine structural design of 3betaHSD1 inhibitors for prostate cancer therapy.
Proc Natl Acad Sci U S A. 2025;122:e2422267122. PubMedAbstract available
SUSHENTSEV N, Hamm G, Manavaki R, McLean MA, et al Spatial metabolomics informs the use of clinical imaging for improved detection
of cribriform prostate cancer.
Proc Natl Acad Sci U S A. 2025;122:e2502423122. PubMedAbstract available
June 2025
PAPPAS K, Ferrari M, Smith P, Nandakumar S, et al BRCA2 reversion mutation-independent resistance to PARP inhibition through
impaired DNA prereplication complex function.
Proc Natl Acad Sci U S A. 2025;122:e2426743122. PubMedAbstract available
April 2025
Correction for Pitzen et al., Comparative transcriptomics reveals a mixed basal,
club, and hillock epithelial cell identity in castration-resistant prostate
cancer.
Proc Natl Acad Sci U S A. 2025;122:e2504762122. PubMed
March 2025
LEE J, Park J, Hur Y, Um D, et al ETV5 reduces androgen receptor expression and induces neural stem-like properties
during neuroendocrine prostate cancer development.
Proc Natl Acad Sci U S A. 2025;122:e2420313122. PubMedAbstract available
February 2025
PITZEN SP, Rudenick AN, Qiu Y, Zhang W, et al Comparative transcriptomics reveals a mixed basal, club, and hillock epithelial
cell identity in castration-resistant prostate cancer.
Proc Natl Acad Sci U S A. 2025;122:e2415308122. PubMedAbstract available
December 2024
VARUZHANYAN G, Chen CC, Freeland J, He T, et al PGC-1alpha drives small cell neuroendocrine cancer progression toward an
ASCL1-expressing subtype with increased mitochondrial capacity.
Proc Natl Acad Sci U S A. 2024;121:e2416882121. PubMedAbstract available
November 2024
KOHRT SE, Novak EJ, Tapadar S, Wu B, et al Small-molecule disruption of androgen receptor-dependent chromatin clusters.
Proc Natl Acad Sci U S A. 2024;121:e2406239121. PubMedAbstract available
October 2024
WANG Z, Yu H, Bao W, Qu M, et al Proteomic and phosphoproteomic landscape of localized prostate cancer unveils
distinct molecular subtypes and insights into precision therapeutics.
Proc Natl Acad Sci U S A. 2024;121:e2402741121. PubMedAbstract available
September 2024
SU XA, Stopsack KH, Schmidt DR, Ma D, et al RAD21 promotes oncogenesis and lethal progression of prostate cancer.
Proc Natl Acad Sci U S A. 2024;121:e2405543121. PubMedAbstract available
August 2024
YU G, Corn PG, Mak CSL, Liang X, et al Prostate cancer-induced endothelial-cell-to-osteoblast transition drives
immunosuppression in the bone-tumor microenvironment through Wnt pathway-induced
M2 macrophage polarization.
Proc Natl Acad Sci U S A. 2024;121:e2402903121. PubMedAbstract available
July 2024
PORNOUR M, Jeon HY, Ryu H, Khadka S, et al USP11 promotes prostate cancer progression by up-regulating AR and c-Myc
activity.
Proc Natl Acad Sci U S A. 2024;121:e2403331121. PubMedAbstract available
ZAIDI S, Park J, Chan JM, Roudier MP, et al Single-cell analysis of treatment-resistant prostate cancer: Implications of cell
state changes for cell surface antigen-targeted therapies.
Proc Natl Acad Sci U S A. 2024;121:e2322203121. PubMedAbstract available
April 2024
HE T, Cheng C, Qiao Y, Cho H, et al Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired
mechanisms of resistance in prostate cancer.
Proc Natl Acad Sci U S A. 2024;121:e2322563121. PubMedAbstract available
December 2023
SUSHENTSEV N, Hamm G, Richings J, McLean MA, et al Imaging tumor lactate is feasible for identifying intermediate-risk prostate
cancer patients with postsurgical biochemical recurrence.
Proc Natl Acad Sci U S A. 2023;120:e2312261120. PubMedAbstract available
November 2023
MAJI S, Pradhan AK, Kumar A, Bhoopathi P, et al MDA-9/Syntenin in the tumor and microenvironment defines prostate cancer bone
metastasis.
Proc Natl Acad Sci U S A. 2023;120:e2307094120. PubMedAbstract available